Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis Publication Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis This study evaluated the pharmacokinetics (PK) and pharmacokinetic–pharmacodynamic (PK–PD) relationship of clazakizumab, an anti–interleukin-6 (IL-6)…Danielle Pillsbury2026 年 3 月 24 日
Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis Publication Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis This article describes how a model-informed drug development (MIDD) approach was used to support the…Certara2026 年 3 月 24 日
Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations Blog Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations Learn how regulatory expectations in clinical pharmacology are evolving and how to build a strategy…Certara2026 年 3 月 24 日
What is GLP (Good Laboratory Practice)? BlogKnowledge Base What is GLP (Good Laboratory Practice)? Read this blog to understand GLP (Good Laboratory Practice) and associated QA audits, and proper…Certara2026 年 3 月 18 日
Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026 Blog 通过模型引导的药物开发促进药物公平:ASCPT 2026 见解 Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…Certara2026 年 3 月 11 日
ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success Blog ADC 首次人体(FIH)剂量选择:成功设计 FIH 研究的关键 Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…Certara2026 年 3 月 3 日
Start right, finish strong: Antibody-drug conjugate (ADC) studies for success On-Demand Webinar Start right, finish strong: 抗体-药物偶联物(ADC)研究成功之道 Learn how to build regulatory-ready first-in-human (FIH) dose strategies for antibody-drug conjugates (ADCs). Discover how…Certara2026 年 2 月 23 日
FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development Blog FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…Certara2026 年 2 月 18 日
How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most Blog How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…Certara2026 年 1 月 26 日
Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy On-Demand Webinar Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy Watch this on-demand webinar to learn how model-based meta-analysis (MBMA), quantitative systems pharmacology (QSP), and…Certara2026 年 1 月 22 日